Drug manufacturer Merck has announced its third round this year of refunds to 340B covered entities for overcharges on select products.
The latest round covers 15 NDCs sold during Q3 2019. The previously announced refunds were for sales during Q1
…
Category: Federal
A federal district court in Arizona has upheld a $23 million arbitration award to the AIDS Healthcare Foundation (AHF) against pharmacy benefits manager (PBM) CVS Caremark for unfair drug reimbursement.
In its November 2019 lawsuit, AHF alleged that CVS Caremark
…
UPDATE Thursday, Sept. 22, 2022, 1:00 p.m. EDT—This story was updated to include new information from HRSA.
The U.S. Health Resources and Services Administration (HRSA) is letting eligible healthcare providers in Puerto Rico enroll in the 340B
…
Federal lawyers last week agreed with national groups that represent 340B hospitals that the U.S. Supreme Court’s June decision to declare illegal Medicare Part B payment cuts in 2018 and 2019 for hospitals’ 340B-purchased drugs “effectively resolves” the groups’ claims
…
Arkansas’s first-of-its-kind law requiring drug makers to honor 340B pricing when covered entities use contract pharmacies to dispense 340B drugs is not preempted by the federal 340B statute since the state law applies only to the acquisition and delivery of
…
A federal district judge in Washington, D.C., put drug manufacturer Merck’s 340B contract pharmacy lawsuit against the federal government on hold until after a federal circuit court in Washington rules in Novartis and United Therapeutics’ 340B contract pharmacy cases.
Lawyers
…
340B HIV provider groups have slammed a recent federal court decision that could have far-reaching implications on access to a host of preventive health care services.
On Sept. 7, Judge Reed O’Connor of the United States District Court for the
…
A federal appeals court in Chicago will hear oral arguments in drug manufacturer Eli Lilly’s 340B contract pharmacy lawsuit against the federal government on Oct. 31, the court announced on Tuesday.
The half-hour session will take place one week after
…
Key stakeholders have offered federal healthcare officials conflicting advice about how best to respond to the U.S. Supreme Court’s June decision striking down a nearly 30% cut in Medicare Part B drug reimbursement for hospitals’ 340B-purchased drugs.
Tuesday was the
…
Late last month, the U.S. Health Resources and Services Administration (HRSA) said on its website that generic drug manufacturer Unichem Pharmaceuticals USA had to repay 340B covered entities for overcharges found during a 340B program compliance audit.
According to Unichem,
…